Literature DB >> 12566712

T cell response to human papillomavirus 16 E7 in mice: comparison of Cr release assay, intracellular IFN-gamma production, ELISPOT and tetramer staining.

Nico Michel1, Peter Ohlschläger, Wolfram Osen, Eva-Jasmin Freyschmidt, Heidrun Guthöhrlein, Andreas M Kaufmann, Martin Müller, Lutz Gissmann.   

Abstract

Successful vaccination against infections by high-risk papillomaviruses aiming at the prevention of cervical cancer most likely requires the induction of neutralizing antibodies and human papillomavirus (HPV)-specific T cells directed against early viral proteins such as E7. Whereas the technology for detection of antibodies is well established, measurement of T cells is more cumbersome and standardization of assays is difficult. By using chromium release assay, ELISPOT, tetramer staining and intracellular IFN-gamma assay, we compared the levels of HPV 16 E7-specific T cells obtained after immunization of C57BL/6 mice with different DNA expression vectors. We found that all four assays gave highly comparable results. ELISPOT can be recommended for future studies as it indicates the presence of activated (i.e. IFN-gamma-secreting) T cells in a quantitative manner and combines high sensitivity with relatively low T cell demand. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12566712     DOI: 10.1159/000067923

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  7 in total

1.  Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays.

Authors:  Dora Wallace; Allan Hildesheim; Ligia A Pinto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

2.  Early detection of dominant Env-specific and subdominant Gag-specific CD8+ lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes.

Authors:  Robert H Mealey; Amin Sharif; Shirley A Ellis; Matt H Littke; Steven R Leib; Travis C McGuire
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

3.  Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.

Authors:  Peter Ohlschläger; Wolfram Osen; Kerstin Dell; Stefan Faath; Robert L Garcea; Ingrid Jochmus; Martin Müller; Michael Pawlita; Klaus Schäfer; Peter Sehr; Caroline Staib; Gerd Sutter; Lutz Gissmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.

Authors:  Lara Kristina Klauer; Olga Schutti; Selda Ugur; Fatemeh Doraneh-Gard; Daniel Christoph Amberger; Nicole Rogers; Doris Krämer; Andreas Rank; Christoph Schmid; Britta Eiz-Vesper; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2021-07-07       Impact factor: 3.747

5.  Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.

Authors:  Marion Nonn; Manuela Schinz; Klaus Zumbach; Michael Pawlita; Achim Schneider; Matthias Dürst; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-02       Impact factor: 4.553

6.  Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell.

Authors:  Françoise Haeseleer; Karsten Eichholz; Semih U Tareen; Nami Iwamoto; Mario Roederer; Frank Kirchhoff; Haesun Park; Afam A Okoye; Lawrence Corey
Journal:  AIDS Res Hum Retroviruses       Date:  2020-11-05       Impact factor: 1.723

7.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Authors:  Yesim Eralp; Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; John M Polo; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-04-07       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.